FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 549 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated... March 5, 2021 EMA Recommends Extension of Therapeutic Indications for Encorafenib and Binimetinib August 23, 2024 Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies May 14, 2021 EMA Recommends Extension of Indications for Tafasitamab December 4, 2025 Load more HOT NEWS 3-in-1 Approach Helps Women in Rural Areas Get Cancer Screenings Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... Advancing Cancer Research as a Married Couple: “Your Stories” Podcast FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens...
